342 related articles for article (PubMed ID: 26282344)
1. Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials.
Thomopoulos C; Skalis G; Michalopoulou H; Tsioufis C; Makris T
Clin Cardiol; 2015 Dec; 38(12):763-9. PubMed ID: 26282344
[TBL] [Abstract][Full Text] [Related]
2. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
[TBL] [Abstract][Full Text] [Related]
3. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.
Murphy SA; Cannon CP; Blazing MA; Giugliano RP; White JA; Lokhnygina Y; Reist C; Im K; Bohula EA; Isaza D; Lopez-Sendon J; Dellborg M; Kher U; Tershakovec AM; Braunwald E
J Am Coll Cardiol; 2016 Feb; 67(4):353-361. PubMed ID: 26821621
[TBL] [Abstract][Full Text] [Related]
4. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
Lancellotti P; Pierard LA; Scheen AJ
Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials.
Battaggia A; Donzelli A; Font M; Molteni D; Galvano A
PLoS One; 2015; 10(4):e0124587. PubMed ID: 25915909
[TBL] [Abstract][Full Text] [Related]
6. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Baigent C; Landray MJ; Reith C; Emberson J; Wheeler DC; Tomson C; Wanner C; Krane V; Cass A; Craig J; Neal B; Jiang L; Hooi LS; Levin A; Agodoa L; Gaziano M; Kasiske B; Walker R; Massy ZA; Feldt-Rasmussen B; Krairittichai U; Ophascharoensuk V; Fellström B; Holdaas H; Tesar V; Wiecek A; Grobbee D; de Zeeuw D; Grönhagen-Riska C; Dasgupta T; Lewis D; Herrington W; Mafham M; Majoni W; Wallendszus K; Grimm R; Pedersen T; Tobert J; Armitage J; Baxter A; Bray C; Chen Y; Chen Z; Hill M; Knott C; Parish S; Simpson D; Sleight P; Young A; Collins R;
Lancet; 2011 Jun; 377(9784):2181-92. PubMed ID: 21663949
[TBL] [Abstract][Full Text] [Related]
7. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.
Navarese EP; Robinson JG; Kowalewski M; Kolodziejczak M; Andreotti F; Bliden K; Tantry U; Kubica J; Raggi P; Gurbel PA
JAMA; 2018 Apr; 319(15):1566-1579. PubMed ID: 29677301
[TBL] [Abstract][Full Text] [Related]
8. Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.
Oyama K; Giugliano RP; Blazing MA; Park JG; Tershakovec AM; Sabatine MS; Cannon CP; Braunwald E
J Am Coll Cardiol; 2021 Oct; 78(15):1499-1507. PubMed ID: 34620406
[TBL] [Abstract][Full Text] [Related]
9. Complementary therapy to target LDL cholesterol: the role of the ezetimibe/simvastatin combination.
Neal RC; Jones PH
Vasc Health Risk Manag; 2006; 2(1):31-8. PubMed ID: 17319467
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia.
Patel JV; Hughes EA
Int J Clin Pract; 2006 Aug; 60(8):914-21. PubMed ID: 16893434
[TBL] [Abstract][Full Text] [Related]
11. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.
Ballantyne CM; Abate N; Yuan Z; King TR; Palmisano J
Am Heart J; 2005 Mar; 149(3):464-73. PubMed ID: 15864235
[TBL] [Abstract][Full Text] [Related]
12. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
Blazing MA; Giugliano RP; Cannon CP; Musliner TA; Tershakovec AM; White JA; Reist C; McCagg A; Braunwald E; Califf RM
Am Heart J; 2014 Aug; 168(2):205-12.e1. PubMed ID: 25066560
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR;
Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
[TBL] [Abstract][Full Text] [Related]
14. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy.
Lorenzi M; Ambegaonkar B; Baxter CA; Jansen J; Zoratti MJ; Davies G
Clin Res Cardiol; 2019 May; 108(5):487-509. PubMed ID: 30302558
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial.
Goldberg AC; Sapre A; Liu J; Capece R; Mitchel YB;
Mayo Clin Proc; 2004 May; 79(5):620-9. PubMed ID: 15132403
[TBL] [Abstract][Full Text] [Related]
16. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Cannon CP; Blazing MA; Giugliano RP; McCagg A; White JA; Theroux P; Darius H; Lewis BS; Ophuis TO; Jukema JW; De Ferrari GM; Ruzyllo W; De Lucca P; Im K; Bohula EA; Reist C; Wiviott SD; Tershakovec AM; Musliner TA; Braunwald E; Califf RM;
N Engl J Med; 2015 Jun; 372(25):2387-97. PubMed ID: 26039521
[TBL] [Abstract][Full Text] [Related]
17. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
[TBL] [Abstract][Full Text] [Related]
18. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
[TBL] [Abstract][Full Text] [Related]
19. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.
Goldberg RB; Guyton JR; Mazzone T; Weinstock RS; Polis A; Edwards P; Tomassini JE; Tershakovec AM
Mayo Clin Proc; 2006 Dec; 81(12):1579-88. PubMed ID: 17165637
[TBL] [Abstract][Full Text] [Related]
20. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
